---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000018"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:23:07.749509+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio closes UK manufacturing, cuts 61% workforce; collaborator to conduct ITIL-306 feasibility studies

## Summary
- Board approved closure of UK manufacturing and clinical operations; UK workforce reduced by ~61%.
- Restructuring costs estimated up to $6.1M for severance and contract terminations; expect completion H1 2024.
- No longer expects to report clinical data from ITIL-306-202 trial in 2024.
- Entered agreement with collaborator for preclinical feasibility studies of ITIL-306 in NSCLC; potential IIT in China.

## SEC filing metadata
- accession: 0001789769-24-000018
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/0001789769-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/til-20240114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000018
- JSON: https://secwatch.observer/filing/0001789769-24-000018.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000018.txt

## Key facts
- Restructurings & Charges
  Instil Bio, Inc. announced a restructuring with charges of up to $6.1 million affecting Manchester, UK manufacturing and clinical trial operations (approximately 61%).
  - Type: restructuring
  - Charge: up to $6.1 million
  - Affected area: Manchester, UK manufacturing and clinical trial operations
  - Headcount: approximately 61%
  source text: report clinical data from the ITIL-306-202 clinical trial in 2024 . In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $6.1 million, including employee termination costs, including severance and other benefits, and contract termination costs. The charges that the Company expects to incur in connection with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/0001789769-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.